Press release
Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference
WILMETTE, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing
About this update from Monopar Therapeutics Inc.
WILMETTE, Ill. , Dec. 03, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that Chandler Robinson , MD, Monopar’s Chief Executive Officer, will participate in a fireside chat along with one-on-one meetings at the 36th Annual Piper Sandler Healthcare Conference . Presentation Details: Date: December 5, 2024 Time: 10:30-10:55 am Eastern Time Location: Lotte New York Palace , NY, NY About Monopar Therapeutics Inc. Monopar Therapeutics is a clinical-stage biotechnology company with late-stage ALXN-1840 for Wilson disease, and radiopharma programs including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers. For more information, visit: www.monopartx.com . CONTACT: Monopar Therapeutics Inc. Investor Relations Karthik Radhakrishnan Chief Financial Officer [email protected] Follow Monopar on social media for updates: Twitter: @MonoparTx LinkedIn: Monopar Therapeutics Source: Monopar Therapeutics Inc.
View stock analysis, news, and events for Monopar Therapeutics Inc.